Sirio Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021
Cash & Equivalents	636.42	595.14	636.03	534.49	1,502	715.54
Short-Term Investments	97.56	98.2	25.17	20	109.26	-
Trading Asset Securities	32.89	5	115.2	200.66	79.13	530.77
Cash & Short-Term Investments	766.87	698.34	776.4	755.14	1,690	1,246
Cash Growth	9.08%	-10.05%	2.81%	-55.32%	35.60%	80.57%
Accounts Receivable	708.99	691.26	702.53	652.86	476.96	372.33
Other Receivables	6.61	11.58	20.81	4.99	4.45	4.27
Receivables	715.6	702.84	723.34	657.85	481.41	376.6
Inventory	471.6	458.24	481.66	481.06	232.58	239.61
Other Current Assets	57.43	62.8	41.54	38.87	28.58	51.99
Total Current Assets	2,011	1,922	2,023	1,933	2,433	1,915
Property, Plant & Equipment	2,241	2,192	2,093	1,913	1,332	1,173
Long-Term Investments	163.53	166.57	52.44	94.11	-	337.79
Goodwill	425.46	427.11	417.1	420.73	163.05	158.59
Other Intangible Assets	442.8	459.89	525.92	544.84	178.33	160.75
Long-Term Deferred Tax Assets	166.6	147.12	81.36	32.48	13.75	16.31
Long-Term Deferred Charges	199.73	207.61	258.14	201.92	59.45	53
Other Long-Term Assets	68.2	68.52	34.66	55.99	7.14	6.57
Total Assets	5,719	5,591	5,486	5,196	4,186	3,820
Accounts Payable	388.91	438.96	393.43	398.13	259.25	195.71
Accrued Expenses	76.38	190.08	191.85	104.39	152.33	79.6
Short-Term Debt	183.77	118.68	54.82	-	0.16	0.12
Current Portion of Long-Term Debt	100.51	97.02	40.59	21.25	-	-
Current Portion of Leases	-	23.37	27.09	42.8	7.26	5.19
Current Income Taxes Payable	47.55	35.33	48.07	11.39	11.03	10.18
Current Unearned Revenue	44.51	43.32	36.92	53.13	25.83	28.22
Other Current Liabilities	248.3	113.35	31.76	120.04	13.84	13.43
Total Current Liabilities	1,090	1,060	824.54	751.13	469.69	332.44
Long-Term Debt	1,213	1,137	1,156	1,049	908.36	852.28
Long-Term Leases	312.79	307.41	328.39	256.16	21.14	16.68
Long-Term Unearned Revenue	96.29	98.17	59.7	65.68	62.4	61.48
Long-Term Deferred Tax Liabilities	38.35	26.75	15.15	28.08	22.69	12.44
Other Long-Term Liabilities	2.14	1.76	461.44	479.47	0.01	-
Total Liabilities	2,752	2,631	2,845	2,630	1,484	1,275
Common Stock	307.64	307.63	235.87	181.56	180.5	180.17
Additional Paid-In Capital	913.81	905.92	500.7	547.5	1,048	1,045
Retained Earnings	1,657	1,607	1,623	1,496	1,278	1,138
Treasury Stock	-69.34	-69.22	-54.31	-44.53	-	-
Comprehensive Income & Other	149.2	191.3	200.88	209.37	195.13	181.35
Total Common Equity	2,958	2,942	2,506	2,390	2,702	2,545
Minority Interest	9.09	17.06	135.36	176.14	-	0.01
Shareholders' Equity	2,967	2,959	2,641	2,566	2,702	2,545
Total Liabilities & Equity	5,719	5,591	5,486	5,196	4,186	3,820
Total Debt	1,810	1,684	1,607	1,369	936.9	874.26
Net Cash (Debt)	-1,043	-985.26	-830.1	-614.1	753.08	372.05
Net Cash Growth	-	-	-	-	102.42%	-43.24%
Net Cash Per Share	-3.41	-3.22	-2.73	-2.02	2.45	1.16
Filing Date Shares Outstanding	304.86	306.19	306.79	304.67	305.04	304.49
Total Common Shares Outstanding	304.86	306.19	304.96	304.67	305.04	304.49
Working Capital	921.58	862.1	1,198	1,182	1,963	1,582
Book Value Per Share	9.70	9.61	8.22	7.84	8.86	8.36
Tangible Book Value	2,090	2,055	1,563	1,424	2,360	2,225
Tangible Book Value Per Share	6.85	6.71	5.12	4.68	7.74	7.31
Buildings	-	1,322	1,067	1,000	890.28	528.67
Machinery	-	1,550	1,390	1,242	974.19	773.89
Construction In Progress	-	168.85	238.4	186.94	69.28	365.12